Flaking light on albinism goes beyond mere awareness; it is a collective effort to dispel misconceptions, foster understanding, and pave the way for accurate diagnosis and comprehensive treatment. According to NIH, the estimated occurrence is between 1:17,000 and 1:20,000. One in seven people are affected by an OCA mutation; the most prevalent variant globally is OCA2. Due to cultural traditions that allow consanguineous marriages, which allows prevalence to exceed 1 in 1000, and a condition known as pseudo-dominance, which occurs when the burden of the recessive allele in a specific family is so great that the recessive characteristic is disproportionately represented, OCA2 is widespread in sub-Saharan Africa. The prevalence of albinism is 1 in 40,000 globally for the OCA1 type, however it is one of the most prevalent forms in America and China (70% of instances), and 1 in 39,000 for OCA2 (most common worldwide), among African Americans (1:10,000), Americans (1:36,000), and Sub-Saharan Africa (1:3,900). The estimated prevalence in New Zealand is 1 in 16,000 people. OCA2 and OCA3 are the most prevalent forms of albinism among black people in Southern Africa.
The importance of albinism awareness lies in dismantling stereotypes, promoting inclusivity, and advocating for those with this condition. Accurate diagnosis is fundamental for tailored care, as albinism presents unique challenges, including vision impairment and heightened susceptibility to skin conditions. With heightened awareness, individuals with albinism can access timely and specialized medical interventions, optimizing their overall health and quality of life. The journey toward effective treatment encompasses not only medical support but also societal acceptance and educational initiatives to empower those affected by albinism. By fostering a culture of awareness, diagnosis, and treatment, we create a more compassionate and informed world for individuals living with albinism.
It is a set of disorders characterised by minimal or absent melanin synthesis, is commonly referred to as albinism. Individuals with albinism experience issues with their skin, hair, and vision. There are evident signs of albinism in a person's complexion, hair, and eyes.
The term "albinism," derived from the Latin albus, which means "white," refers to a set of inherited disorders marked by low or non-existent melanin in ectoderm-derived tissues, particularly the skin, hair, and eyes, which results in a distinctive pallor. Oculocutaneous albinism is the most frequently considered presentation (OCA). Melanin synthesis mistakes give rise to a series of genetic illnesses known as OCA, which share phenotypic similarities. The eyes and skin experience the most dramatic impacts, as the name suggests. Depending on the OCA subtype, the skin symptoms might vary greatly in severity and appearance. Because melanin is essential to the development of the ocular tissues in utero, optic nerve fibres that are misdirected result in more consistent ocular symptoms of the disease.
Causes
When the body is unable to synthesise or spread melanin due to one of numerous genetic abnormalities, albinism results. Families passed these defects on to one another (inherited).
The term "oculocutaneous albinism" refers to the most severe type of the disease. Individuals with this kind of albinism have pink or white skin, hair, and iris colour. They also experience visual issues.
Only the eyes are impacted by ocular albinism type 1 (OA1), another kind of albinism. The individual's skin and eye colours are typically within normal limits. But an examination of the eyes will reveal that the retina, or back of the eye, is colourless.
A single gene mutation results in Hermansky-Pudlak syndrome (HPS), a kind of albinism. It develops in cases of blood disorders, as well as bowel, renal, and lung conditions.
Symptoms
The following symptoms are present in people with albinism:
Vision issues are a common occurrence in albinism and might include:
In order to manage ocular symptoms and maximise visual potential—which has further implications for education, esteem for oneself, overall health and wellness, and cognitive development—early identification is necessary.
Genetic Testing
In genetic testing, DNA is examined. DNA is a chemical database that contains instructions on how the body should work. Genetic testing reveals modifications or mutations. In laboratories, there are three main kinds of genetic testing available: molecular (which examines for minuscule DNA mutations), biochemical (which measures the amount of protein made by genes), and cytogenetic (which examines entire chromosomes).
Some commonly used genetic testing kits are DNA extraction kits, Polymerase Chain Reaction Kits, DNA Sequencing kits, Sanger sequencing kits, etc. The manufacturing of these kits is undertaken by various biotechnology and life science companies. Some notable companies are Thermo Fisher Scientific, Illumina, Qiagen, Roche Diagnostics, etc.
Electroretinogram
The electrical response of the rods and cones, the light-sensitive cells of the eye, is measured by a procedure called electroretinography. Together with input from retinal glia, the ERG is produced by direct currents produced by retinal neurons. Crucially, under physiological settings, the ERG can be captured non-invasively and provides an objective measure of retinal function. A thin fibre electrode applied to the cornea or an electrode inserted into a contact lens for the cornea are commonly used to capture ERGs. These electrodes allow the ocular surface to record the electrical activity produced by the retina. Diffuse flashes or patterned stimuli can trigger the ERG.
Diagnostic Market Players |
Diagnostic Products |
Mckesson Corporation |
AncestryDNA |
Microtrack Surgicals |
23andMe |
Evolution Vision |
MyHeritage DNA |
Epic Systems Corporation |
EP-1000 |
Namco National Medicine Co |
EvokeDx® |
Nutech Jetting Equipments India Private Limited |
ColorFlash® |
Konan Medical USA |
NEURO-ERG® |
Ank Cares Pvt Ltd |
|
Allied International Llc |
|
Aura Biotechnologies Private Limited |
|
Tomey |
|
Roche Diagnostics |
|
Diagnosys |
|
There is no known cure for the hereditary disorder albinism, which affects people throughout their lives hence most doctors do not prescribe the medication to patients. As a result, the main goals of treatment are to reduce symptoms and monitor skin changes.
The US Food and Drug Administration (FDA) has approved Nitisinone as a treatment for hereditary tyrosinemia type 1, which is characterised by elevated plasma tyrosine levels and increased pigmentation of the hair and eyes. Nitisinone (Orfadin) may soon be used as an eye albinism therapy.
Surgery
Self-care
Treatment Market Players |
Johnson & Johnson Services |
HumanOptics |
Bayer |
GlaxoSmithKline PLC |
Celgene |
Merck |
AbbVie |
Laboratoires Genevrier |
Allerga Clinuvel Pharmaceuticals |
AVITA Medicals |
Allergan |
Mckesson Corporation |
Clinuvel Pharmaceutical |
CENTOGENE |
Global demand for albinism drugs is being driven by a number of factors, including increased incidence of genetic diseases, expanding knowledge of albinism treatment options, technical advancements, growing regulatory bodies' particular instructions, and growing albinism research. Approximate estimates place the prevalence of OCA in western industrialised countries at 1 in 17,000 worldwide. Because hereditary gene deficiencies account for 80% of rare disorders, albinism falls within the category of rare diseases. However, there are often no reliable treatments for these illnesses. Because of this, the market for drugs for albinism is extremely narrow.
Phase 2 |
Immune Disorder HSCT Protocol |
DiseaseLandscape Insights (DLI) assists manufacturers in developing and implementing viable remedies to interrupt and manage Albinism epidemics. Furthermore, there is an increasing need for diagnostic tools, clinical evaluations, and innovative therapies as a result of greater awareness and estimated epidemics.
DLI services offer essential knowledge and expertise to major stakeholders involved in the manufacture of therapeutic goods. DiseaseLandscape Insights' support makes it easier for market participants to organize and carry out clinical trials for innovative medicines and pharmaceuticals, patient recruiting tactics, and regulatory compliance.
Ultimately, this encourages the leaders to perform qualitative research, explore the manufacturing organizations, and learn about raw material suppliers.
How we can help?